Rodman & Renshaw Upgrades Viropharma (VPHM) to Market Outperform
More News related to LEVP
- Rodman & Renshaw Upgrades Viropharma (VPHM) to Market Outperform
- Jefferies Downgrades Lev Pharmaceuticals (LEVP) to Hold
- Notable Mergers and Acquisitions of the Day 7/15 (VPHM/LEVP, ETFC/BNS, MOS)
- ViroPharma (VPHM) To Acquire Lev Pharmaceuticals (LEVP) For $442.9 Million
- Jefferies & Co Initiates Coverage on Lev Pharmaceuticals (LEVP) with a Buy
More News related to VPHM
- Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated
- ViroPharma to Present at Three November Healthcare Conferences
- ThinkEquity Upgrades ViroPharma (VPHM) to Buy
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Morning Movers 10/28: CSBC, QTM, ANIK, RSYS, PEET, WSII Higher; CALC, KSP, PSYS, VCLK, VPHM, GT Lower
More News related to Upgrades
- Notable Late-Afternoon ETF Movers for 11/25: UNG, GDX, XRT Higher; UUP Lower
- Notable 52-Week High's and Low's: BMY, JCG, PBR, SLW, GOOG, INCY, NTAP, QADI, GOLD, BONT Higher; SPWRB Low
- Unusual 11 Mid-Day Movers 11/25: RTK, QADI, QBC, KBX Higher; BNHNA, DRAM, TBH, CWTR Lower
- Afternoon ETF Check: UNG, XRT, EWJ Up; VNM, RSX Down
- Notable Analyst Ratings Changes 11/25: EXXI, IWA, VPRT Upgraded; BNHN, NRG, GTE Downgraded
Rodman & Renshaw upgrades Viropharma (Nasdaq: VPHM) from Market Perform to Market Outperform. Price target $18.
Rodman analyst says, "We are upgrading our rating on ViroPharma to Market Outperform following the announcement on Friday that the FDA has approved Cinryze for the prophylactic treatment of hereditary angioedema (HAE). We are highly confident that following the approval of Cinryze, the merger agreement between ViroPharma and Lev Pharmaceuticals (Nasdaq: LEVP) will be consummated directly following the LEVP shareholder vote on October 21st."
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious infectious diseases.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
